Hepatocellular Cancer

P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028

P=N/A, N=50, Recruiting, Asan Medical Center | Trial primary completion date: Aug 2025 --> Aug 2026 | Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | Trial completion date: Aug 2025 --> Aug 2026

Elevated EphA4 levels in serum are associated with higher risk of PH after ischemic stroke, especially among patients showing greater permeability of the BBB as reflected in higher ipsilateral FED on computed tomography perfusion.

This research highlights the pivotal role of TOE1 in HCC, indicating its promise as a novel target for early detection, therapeutic strategies, immunological intervention, and prognosis assessment in HCC. These findings provide fresh perspectives for precision medicine in the context of HCC.

Furthermore, HCC cells with overexpressed Maf1 have heightened sensitivity to Aurora-A inhibitors, suggesting a potential therapeutic vulnerability. Our study uncovers a non-canonical, oncogenic role of Maf1 in HCC and highlights the Aurora-A-Maf1 axis as a promising target for personalized cancer therapy.

OS can be accurately predicted in patients with HCC receiving sorafenib by combining certain radiomics features with clinical metadata, centered primarily on baseline characteristics.

Our in vivo data demonstrate that SLU7 is a promising, versatile target for possibly diverse cancers. Its multimodal mechanism offers potential to overcome tumor heterogeneity, reverse immune tolerance, and enhance immunotherapy efficacy.

P2, N=20, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

In preclinical models, the administration of Def-LNP@mRNATCPTP successfully eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved the therapeutic responsiveness of HCC to cancer vaccine and immune checkpoint blockade therapy. Def-LNP@mRNATCPTP represents a potential therapeutic strategy for MAFLD and MAFLD-related HCC, potentially offering treatment paradigms for immunotherapy for HCC and metabolic liver diseases.

Moreover, GPPN improves magnetic resonance imaging (MRI) signals of liver fibrosis to enable more accurate assessment of disease progression. Overall, GPPN presents considerable potential for the precise diagnosis and effective therapy of liver fibrosis.

A nomogram centered on UTP3 yielded a 1-year AUC of 0.693. This multi-omics study establishes UTP3 as a key regulator connecting epigenetic alterations, immune suppression, and tumor progression in LIHC.